<DOC>
	<DOCNO>NCT01718652</DOCNO>
	<brief_summary>The purpose study determine single dose cyclosporin affect pharmacokinetics ( ie , body affect drug ) multiple dos canagliflozin ( JNJ-28431754 ) . The safety tolerability canagliflozin also assess healthy volunteer .</brief_summary>
	<brief_title>A Study Assess Effects Cyclosporine Pharmacokinetics Safety Canagliflozin ( JNJ-28431754 ) Healthy Volunteers</brief_title>
	<detailed_description>This study open label ( volunteer study staff know identity assign treatment ) , single-center , multiple-dose study determine cyclosporin ( drug reduce activity patient 's immune system ) affect pharmacokinetics canagliflozin ( drug currently investigate treatment type 2 diabetes mellitus ) . The study consist 3 phase : screening phase , open-label treatment phase , end-of study ( follow-up ) phase . Each volunteer participate study approximately 47 day .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Must body mass index 18 30 kg/m2 ( inclusive ) , body weight less 50 kg If woman , must either postmenopausal , define spontaneous menses least 18 month amenorrhea least 6 month surgically sterile ( hysterectomy , tubal ligation ) History smoking use nicotinecontaining substance within previous 2 month Have history current medical illness consider clinically significant Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cyclosporine</keyword>
</DOC>